[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-362175-105":59,"doc-detail-362175-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","pi3k-inhibitor-and-degrader-inavolisib-can-co-opt-fgfr2-to-enhance-responses-in-patients-with-pik3ca-mutated-solid-tumors-and-in-preclinical-models","PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models","","PIK3CA mutations frequently drive solid tumors, and the PI3K inhibitor inavolisib both inhibits p110α and promotes degradation of mutated p110α. A first-in-human phase 1 study evaluated oral inavolisib in patients with PIK3CA-mutated solid tumors to define maximum tolerated dose and safety, with correlative ctDNA analyses. Preclinical cell-line and xenograft work clarified FGFR2’s role and showed synergy with FGFR2 inhibition, delayed resistance, and enhanced antitumor activity in vivo.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pi3k-inhibitor-and-degrader-inavolisib-can-co-opt-fgfr2-to-enhance-responses-in-patients-with-pik3ca-mutated-solid-tumors-and-in-preclinical-models/362175/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pi3k-inhibitor-and-degrader-inavolisib-can-co-opt-fgfr2-to-enhance-responses-in-patients-with-pik3ca-mutated-solid-tumors-and-in-preclinical-models/362175.png","ImageObject",300,407,{"name":92,"@type":93},"Miles","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-21","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",12,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main biological rationale for combining FGFR2 and p110α in this study?","Question",{"text":113,"@type":114},"The findings describe a cooperative interaction where FGFR2 signaling engages pathways that facilitate mutated p110α degradation, increasing inavolisib effectiveness.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How was inavolisib evaluated clinically in this work?",{"text":118,"@type":114},"A first-in-human phase 1 study (NCT03006172) assessed oral inavolisib in patients with PIK3CA-mutated solid tumors to determine maximum tolerated dose, safety, and related correlative analyses including ctDNA.",{"name":120,"@type":111,"acceptedAnswer":121},"What preclinical evidence supported FGFR2’s role and the combination strategy?",{"text":122,"@type":114},"Cell lines and xenografts showed that oncogenic FGFR2 signaling enhanced inavolisib sensitivity and that combining with FGFR2 inhibitors produced synergy while delaying resistance.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},362175,1790248200,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":31,"preview_page_count":19,"preview_urls":145},13056703019404,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models  \nDejan Juric1, Kyung Song2, Radia M. Johnson2, Melissa K. Accordino3, Philippe L. Bedard4, Andrs Cervantes5, Valentina Gambardella5, Erika Hamilton6, Antoine Italiano7,8, Kevin Kalinsky9, Ian E. Krop10, Mafalda Oliveira11, Cristina Saura11, Peter Schmid12, Nicholas C. Turner13, Andreea Varga14, Steven Gendreau15,  \nMichael S. Hwang15, Zheng Kuang15,16, Jeffrey T. Lau17, Eva Lin18, Trang Pham2, Danilo Maddalo17, Matthew G. Rees19, Melissa M. Ronan19, Jennifer A. Roth19, Scott Martin18, Nicole M. Sodir17, Ethan S. Sokol15,16, Zachary J. Whitfield20, Alice Wong21, Robert L. Yauch2, Junko Aimi15, Sravanthi Cheeti22, Jill Fredrickson23, Stephanie Hilz15, Marc Hafner2,24, Katherine E. Hutchinson15, Yanling Jin25, Ubong Peters26, Daniel Zingg2, Stephanie Royer-Joo26, Noopur Shankar27, Jennifer L. Schutzman26, Komal L. Jhaveri28, and Anwesha Dey2  \n|  |  | A |  | B | S |  | T | R |  | A |  | C | T |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |\n|  | Purpose: PIK3CA mutations frequently drive solid tumors, particularly hormone receptor–positive breast cancer. Inavolisib, an ATP-competitive p110α inhibitor, also promotes the degradation of mutated p110α . PI3K inhibitors have generally shown modest single-agent activity and have safety concerns.\u003Cbr>Patients and Methods: A first-in-human phase 1 study (NCT03006172) evaluated oral inavolisib in patients with PIK3CAmutated solid tumors to determine the maximum tolerated dose and safety. Correlative analyses included ctDNA. Preclinical studies in cell lines and xenografts elucidated the role of FGFR2.\u003Cbr>Results: The maximum tolerated dose was 9 mg daily, with a manageable safety profile (e.g. , hyperglycemia and diarrhea) . Inavolisib showed linear pharmacokinetics, consistent pharmacodynamic modulation, and antitumor activity in hormone receptor–\u003Cbr>􀀶 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | positive PIK3CA-mutated breast cancer (26% objective response rate and 45% clinical benefit rate). FGFR2 hotspot mutations in ctDNA were strongly associated with clinical benefit. Preclinically, oncogenic FGFR2 signaling enhanced inavolisib sensitivity by engaging HER3, RAS, and p85β, that facilitated mutated p110α degradation, surpassing nondegrading inhibitors. Combination therapy with FGFR2 inhibitors showed synergy and delayed resistance.\u003Cbr>Conclusions: These findings highlight a novel cooperativity between FGFR2 and p110α that boosts the effectiveness of inavolisib. The data support advancing precision oncology beyond single biomarkers to complex algorithms utilizing co-occurring alterations, suggesting that combining inavolisib with FGFR2 inhibitors may offer enhanced and more durable responses in PIK3CA/ FGFR2-altered tumors. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |\n\nIntroduction  \nPI3K is a multidomain lipid kinase that, upon activation b","cbCaitiAGVF4vl4G","https://ap.wps.com/l/cbCaitiAGVF4vl4G","pdf",9993107,"English","# Purpose\n# Patients and Methods\n# Results\n# Conclusions\n# Introduction","[{\"question\":\"What is the main biological rationale for combining FGFR2 and p110α in this study?\",\"answer\":\"The findings describe a cooperative interaction where FGFR2 signaling engages pathways that facilitate mutated p110α degradation, increasing inavolisib effectiveness.\"},{\"question\":\"How was inavolisib evaluated clinically in this work?\",\"answer\":\"A first-in-human phase 1 study (NCT03006172) assessed oral inavolisib in patients with PIK3CA-mutated solid tumors to determine maximum tolerated dose, safety, and related correlative analyses including ctDNA.\"},{\"question\":\"What preclinical evidence supported FGFR2’s role and the combination strategy?\",\"answer\":\"Cell lines and xenografts showed that oncogenic FGFR2 signaling enhanced inavolisib sensitivity and that combining with FGFR2 inhibitors produced synergy while delaying resistance.\"}]","PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models | PDF",1790146655,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47ac688f8c277f4eba6ca231b090bba9.webp",983,1315,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/17a3c74968a31831c64f32ff8db1a330.webp",982,1314,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aee24b733636bba9a828f7d60494f136.webp",981,1312,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6da24dba8e0cc17be1ddd7b013844aa0.webp",980,1311]